GALR2 and colorectal carcinoma: The GAL2R gene has been suggested in CRC as a chemosensitive methylation candidate to bevacizumab, since HCT116 CRC cells overexpressing GAL2R were more chemosensitive to the monoclonal antibody than control cells [181].